Research programme: small molecule anti-psychotic therapeutics - Solvay/Wyeth
Latest Information Update: 02 Dec 2008
At a glance
- Originator Solvay Pharmaceuticals; Wyeth
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 15 Jan 2007 Preclinical trials in Psychotic disorders in USA (unspecified route)